Clinical Trial

QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma

Study acronym: QL1706
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I trial to assess the safety and preliminary efficacy of QL1706 in Treating Advanced Hepatocellular Carcinoma Patients refractory to prior immunotherapy.
Trial Details
NCT Number NCT06822985
Lead Sponsor Wan-Guang Zhang
Collaborators: Qilu Pharmaceutical Co., Ltd.
Conditions HCC - Hepatocellular Carcinoma
Enrollment 21 participants
Start Date 2025-02-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-12